Radiol Oncol 2020; 54(3): 353-363. doi: 10.2478/raon-2020-0046 353 research article Consolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapy Karmen Stanic1,2, Martina Vrankar1,2, Jasna But-Hadzic1,2 1 Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia 2 Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia Radiol Oncol 2020; 54(3): 353-363. Received 9 March 2020 Accepted 4 July 2020 Correspondence to: Assist. Prof. Jasna But-Hadžić, M.D. PhD., Institute of Oncology Ljubljana, Department of Radiotherapy, Zaloška 2, 1000 Ljubljana. E-mail: jbut@onko-i.si Disclosure: No potential conflicts of interest were disclosed. Background. Consolidation radiotherapy (cRT) in extended disease small cell lung cancer (ED-SCLC) showed im- proved 2-year overall survival in patients who responded to chemotherapy (ChT) in CREST trial, however results of two meta - analysis were contradictive. Recently, immunotherapy was introduced to the treatment of ED-SCLC, making the role of cRT even more unclear. The aim of our study was to access if consolidation thoracic irradiation improves survival of ED-SCLC patients treated in a routine clinical practice and to study the impact of cRT dose on survival. We also discuss the future role of cRT in the era of immunotherapy. Patients and methods. We retrospectively reviewed 704 consecutive medical records of patients with small cell lung cancer treated at the Institute of Oncology Ljubljana from January 2010 to December 2014 with median follow up of 65 months. We analyzed median overall survival (mOS) of patients with ED-SCLC treated with ChT only and those treated with ChT and cRT. We also compared mOS of patients treated with different consolidation doses and performed univariate and multivariate analysis of prognostic factors. Results. Out of 412 patients with ED-SCLC, ChT with cRT was delivered to 74 patients and ChT only to 113 patients. Patients with cRT had significantly longer mOS compared to patients with ChT only, 11.1 months (CI 10.1–12.0) vs. 7.6 months (CI 6.9–8.5, p < 0.001) and longer 1-year OS (44% vs. 23%, p = 0.0025), while the difference in 2-year OS was not significantly different (10% vs. 5%, p = 0.19). The cRT dose was not uniform. Higher dose with 45 Gy (in 18 fractions) resulted in better mOS compared to lower doses 30–36 Gy (in 10–12 fractions), 17.2 months vs. 10.3 months (p = 0.03) and statistically significant difference was also seen for 1-year OS (68% vs. 30%, p = 0.01) but non significant for 2-year OS (18% vs. 5%, p = 0.11). Conclusions. Consolidation RT improved mOS and 1-year OS in ED-SCLC as compared to ChT alone. Higher dose of cRT resulted in better mOS and 1-year OS compared to lower dose. Consolidation RT, higher number of ChT cycles and prophylactic cranial irradiation (PCI) were independent prognostic factors for better survival in our analysis. For patients who received cRT, only higher doses and PCI had impact on survival regardless of number of ChT cycles received. Role of cRT in the era of immunotherapy is unknown and should be exploited in further trials. Key words: small cell lung cancer; ED-SCLC; radiotherapy; consolidation radiotherapy; immunotherapy Introduction Small cell lung cancer (SCLC) represents only small proportion of lung cancer but is an aggressive dis- ease and unfortunately diagnosed already in ad- vanced stage in majority of patients.1 In Slovenia 15.3% of lung cancer patients were diagnosed with SCLC in 2014, and majority had metastatic dis- Radiol Oncol 2020; 54(3): 353-363. Stanic K et al. / Consolidation radiotherapy in extended disease small cell lung cancer354 ease.2 In recent years, percentage of patients with metastatic disease has slightly increased, but this might only be due to better staging with incorpora- tion of PET/CT and brain MRI.3,4 SCLC is highly chemo-sensitive disease and standard treatment for metastatic patients is platinum based chemotherapy (ChT), usually combined with etoposide or irinotecan.5,6 Almost 75% of the patients have persisting intra-thoracic disease after treatment with ChT and addition of chest radiotherapy (RT) aimed to improve progres- sion free survival (PFS) and overall survival (OS) in those patients.7 Prospective randomized CREST study suggested survival benefit of added thoracic RT in addition to PCI for ED-SCLC patients who respond to ChT; however, OS at 1-year, which was the primary endpoint of the study, was not signifi- cantly improved.8 Prospective RTOG 0937 study also failed to show 1-year survival benefit, though disease progression was delayed.9 On the other hand, some retrospective studies showed benefit of consolidation RT (cRT).10-13 None of the prospec- tive and only rare retrospective studies specifically researched the effect of radiation dose on survival. In addition, selective patients might benefit from prophylactic cranial irradiation (PCI), which showed increase in overall survival if added to ED- SCLC after ChT.14 In spite of that, the median over- all survival (mOS) of metastatic disease remains poor, ranging from 8 to13 months, with only 5% of patients being alive at 2 years.15 Recently, immuno- therapy with atezolizumab or durvalumab added to ChT without chest irradiation has shown in- creased mOS in first line treatment of patients with metastatic SCLC, therefore in the future the role of radiotherapy would need to be reconsidered.16,17 The aim of our study was to access if cRT im- proves survival of ED-SCLC patients treated in a routine clinical practice of tertiary single centre and to study the impact of cRT dose on survival. We also discuss whether the cRT still has the role in the treatment of ED SCLC in the era of immu- notherapy. Patients and methods We retrospectively reviewed medical records of consecutive patients with SCLC treated at the Institute of Oncology Ljubljana during the five year period, from January 2010 to December 2014. Median follow up was 65 months. Not all metastatic SCLC patients were referred to our center for treatment; however, during the pe- riod studied, we were the only radiotherapy center in the country and all patients that needed irradia- tion, based on multidisciplinary tumor board deci- sion, were treated at our institution. Only patients who had at least stable disease or regression of dis- ease after chemotherapy were eligible for thoracic consolidation radiotherapy. The decision about the dose was at the discretion of radiation oncologist and based on the volume of the tumor and perfor- mance status of the patient since during the time period studied there was no uniform dose suggest- ed in any of the guidelines. Diagram in Figure 1 outlines the selection pro- cess. During 5 year period 704 consecutive patients with SCLC were treated at the Institute of oncology Ljubljana, 412 with extended disease and 292 with locally advanced disease. Among all ED-SCLC pa- tients, 59 (14.3%) were treated with BSC, 67 (16.2%) patients with RT only, 113 (27.4%) with ChT only and 173 (41.9%) with combined ChT and RT. RT was either consolidation RT (cRT), delivered to 74 patients or any other type of RT which included urgent RT, partly concurrent ChT or RT that was prematurely closed due to any reason (99 patents). The following parameters were recorded: demo- graphic and clinical characteristics, date of diagno- sis, TNM stage, treatment characteristics, including chemotherapy and radiation therapy details, meta- static locations and date of death or last follow up. FIGURE 1. Diagram of patients’ selection process. Radiol Oncol 2020; 54(3): 353-363. Stanic K et al. / Consolidation radiotherapy in extended disease small cell lung cancer 355 Chemotherapy Of Majority (47.5%) of patients received all 6 planned cycles of chemotherapy, 66 patients (35.3%) received less than 4 cycles of ChT. Etoposide with platinum was the most frequent combination (83.8%), the rest received anthracycline based ChT. In the group with cRT were less patients who re- ceived 4 ChT cycles or less. Radiotherapy Radiotherapy with linear accelerators (photon beam 6-10MV), based on 3D CT-based conformal radiation therapy planning, started after ChT. There was no difference in frequency of patients who started before (29 patients) and after 4 weeks (25 patients) of ChT completion. Prophylactic cra- nial irradiation was delivered with two opposed lateral fields with the dose of 25 Gy in 10 fractions using 2D planning and 6MV photon beam energy. Statistical analysis The primary endpoints in this analysis were mOS, 1-year and 2-year OS of ED-SCLC patients treated with ChT only versus patients treated with ChT and cRT and those receiving higher vs. lower dose of cRT. Median OS was calculated from the time of diagnosis to the time of death due to any cause or last follow up visit. Kaplan-Meier (KM) method and log-rank test were used for comparison of sur- vival curves between different groups. Cox pro- portional hazards algorithm was used for univari- ate and multivariate analysis. Association between subgroups and clinico-pathological characteristics of patients were tested using chi-square method. All p values reported were based on 2 side hypoth- esis. The statistical analysis was computed using SPSS v.20 statistical package. Ethical consideration This survey was approved by Institutional Ethics Committee and Institutional Review Board in December 2017. Results We performed two analysis. In our first analysis we included 187 patients, 113 patients treated with Cht only were compared to 74 patients treated with ChT and cRT. Different fractionation schemes were TABLE 1. Patients’ characteristics: chemotherapy only vs. chemotherapy with consolidation radiotherapy ChT only ChT with cRT p n (%) n (%) Gender 187 (100) 113 (60.4) 74 (39.6) Male 126 (67.4) 81 (71.1) 45 (60.1) 0.12 Female 61 (32.6) 32 (28.9) 29 (39.9) Age median (range) 63 (42-80) 61 (42-80) 63 (47-80) 0.24 < 65 122 (65.2) 70 (61.9) 52 (70.3) > 65 65 (34.8) 43 (38.1) 22 (29.7) Number of ChT cycles* < 4 66 (35.3) 51 (47.2) 15 (20) <0.001 > 4 113 (60.4) 57 (52.8) 56 (80) T stage 0.23 T1–2 32 (17.1) 20(17.7) 12 (16.2) T3-4 122 (65.2) 69 (61) 53 (71.6) Tx 33 (17.7) 24 (21.3) 9 (12.2) N stage 0.56 N0–2 71 (38) 40 (35.4) 31(41.9) N3 91(48.7) 56 (49.6) 35 (47.3) Nx 25 (13.3) 17 (15) 8 (10.8) Metastases location** Brain 44 (23.5) 28 (24.8) 16 (21.6) 0.61 Liver 86 (46) 57 (50.4) 29 (39.2) 0.13 Bone 42 (22.5) 28 (24.8) 14 (18.9) 0.34 Adrenal gland 38 (20.3) 23 (20.4) 15 (20.3) 0.98 Other 92 (49.2) 62 (54.9) 30 (40.5) 0.06 Number of metastatic locations 1 105 (56.1) 55 (48.7) 50 (67.6) 0.01 > 2 82 (43.9) 58 (51.3) 24 (23.4) PCI Yes 41 (21.9) 20 (17.6) 21 (28.4) 0.08 no 146 (78.1) 93 (82.4) 53 (71.6) * for 8 patients we were not able to retrieve the exact number of cycles from medical records, percentage of patient is calculated only for those with known number of cycles (179); ** some patients had more than 1 metastatic location, percentages are calculated as part of all patients in a group; ChT = chemotherapy; cRT = consolidation radiotherapy; PCI = prophylactic cranial irradiation Radiol Oncol 2020; 54(3): 353-363. Stanic K et al. / Consolidation radiotherapy in extended disease small cell lung cancer356 used for cRT. The doses in cRT were not uniform, therefore we divided them into 3 groups: below 30 Gy, 30–36 Gy and 45 Gy. Only 59 patients with doses above 30 Gy were included in our second analysis of dose comparison. Patient characteristics Baseline characteristics of 187 patients, divided to those with ChT only and those who also received cRT are presented in Table 1. The two groups were balanced regarding gender, age, T and N stage and metastatic locations. However, lower number of patients received 4 or less cycles of ChT and had 2 or more metastases present at diagnosis in ChT plus cRT group. Table 2 present baseline characteristics of 59 patients who received > 30 Gy cRT, comparing those with higher dose (45 Gy) cRT and lower dose (30–36 Gy). In summary, median age was 63 years, more than half were men. Majority of patients were younger than 65 years. Unfortunately, reliable PS could not be retrieved from medical records for half of the patients and more than 10% of patients had PS 2-3 before cRT. Non-significantly more pa- tients had larger tumors (T3-4) and more extended lymph node disease (N3) in the group treated with lower dose RT. For more than 10% of patients with central tumors, the size of tumor (T) or nodal sta- tus could not be determined. Fifty-eight percent of patients had one metastatic site. The most frequent site of metastases were liver. Less than third of pa- tients had PCI. Survival data Median OS of patients who had either BSC or RT only was poor, 1.86 and 2.42 months, respectively. Patients who had any form of additional chest irra- diation (173 patients) had significantly better mOS than 113 patients with ChT only (9.9m vs. 7.6m, p = 0.002). Consolidation RT was delivered to 74 patients. Those patients had significantly longer mOS com- pared to 113 patients with ChT only as presented in Figure 2, 11.1 months (CI 10.1–12.0) vs. 7.6 months (CI 6.9–8.5), p < 0.001. They also had significantly longer 1-year OS (44% vs. 23%, p = 0.0025), but non significantly longer 2-year OS (10% vs. 5%, p = 0.19). Univariate survival analysis (UVA) for patients with or without cRT included the following vari- ables: cRT, gender, age, number of ChT cycles, T and N stage, metastatic location, number of meta- TABLE 2. Patients’ characteristics: higher vs. lower dose of radiotherapy All 45 Gy 30-36 Gy p n (%) n (%) n (%) Gender 59 15 44 Male 35 (60) 6 (40) 29 (65.9) 0.078 Female 24 (40) 9 (60) 15 (34.1) Age median 62 (42–76) 60 (54–73) 62 (42–76) 0.12 < 65 42 (71.2) 13 (68.7) 29 ( 65.9) > 65 17 (28.8) 2 (13.3) 15 (34.1) Number of ChT cycles < 4 12 (20.3) 2 (13.3) 10 (22.7) 0.37 > 4 44 (74.6) 13 (68.7) 31 (70.5) unknown 3 (5.1) 0 (0) 3 (6.8) PS before RT 0.66 0-1 22 (37.3) 5 (33.3) 17 (38.6) 2–3 7 (11.8)) 1 (6.67) 6 (13.6) unknown 30 (50.9) 9 (0.6) 21 (47.8) T stage 0.15 T1–2 8 (13.6) 4 (26.7) 4 (9.1) T3–4 42 (71.2) 8 (53.3) 34 (77.3) Tx 9 (15.3) 3 (20) 6 (13.6) N stage 0.69 N0–2 24 (40.7) 7 (46.7) 17 (38.6) N3 29 (49.2) 6 (40) 23 (52.3) Nx 6 (10.1) 2 (13.3) 4 (9.1) Metastases location* Brain 14 (23.7) 5 (33.3) 9 (20.5) 0.31 Liver 27 (45.7) 6 (40) 21 (47.7) 0.60 Bone 13 (22) 3 (30) 10 ( 22.7) 0.82 Adrenal gland 15 (25.4) 3 (30) 12 (27.3) 0.57 Other 21 (35.6) 3 (30) 19 (43.2) 0.10 Number of metastatic locations 1 34 (57.6) 10 (66.7) 24 (54.5) 0.41 > 2 25 (42.4) 5 (33.3) 20 (45.4) Timing of RT** 0.15 < 4 weeks after ChT 17 (53.1) 6 (75) 11 (45.9) > 4 weeks after ChT 15 (46.9) 2 (25) 13 (54.1) PCI Yes 17 (28.8) 5 (33.3) 12 (27.3) 0.65 * some patients had more than one metastatic site; ** for 31 missing patients no reliable data of the completion chemotherapy date could be retrieved from the medical records; Ch =- chemotherapy; Gy = Gray; N = lymph nodes; PS = performance status; RT = radiotherapy; T = tumour Radiol Oncol 2020; 54(3): 353-363. Stanic K et al. / Consolidation radiotherapy in extended disease small cell lung cancer 357 patients by Zhu et al., survival results were much better than in our analysis, with mOS of 17 months for patients in ChT plus cRT group and 9.3 months for those with ChT only, and 2-year OS of 35% and 17%, respectively. They delivered higher cRT dose (range 40–60 Gy) and had comparable mOS (17.2 months) as our group of patients irradiated with 45 Time (months) 483624120 O ve ra ll Su rv iv al 1,0 0,8 0,6 0,4 0,2 0,0 p<0.001 HR 1.73 (CI 1.27-2.34) mOS: 7.6 m vs 11.1 m ChT + cRT-censored ChT only-censored ChT + cRT, n=74 ChT only, n=113 ChT only vs ChT + cRT Time (months) 483624120 O ve ra ll Su rv iv al 1,0 0,8 0,6 0,4 0,2 0,0 p=0.02 45-censored 30-36-censored 45 Gy, n=44 30-36 Gy, n=15 RT 30-36 Gy vs 45 Gy mOS: 10.3 m vs 17.2 m HR 1.73 (CI: 1.27-3.56) FIGURE 2. Overall survival of patients treated with chemotherapy (Cht only) vs. chemotherapy and consolidation radiotherapy (ChT + cRT). FIGURE 3. Overall survival of patients treated with higher (45 Gy) vs. lower (30-36 Gy) dose of irradiation. static locations and PCI. Presence of cRT, female gender, number of ChT cycles (4 or less and more than 4) and PCI were significant in univariate analysis and were tested in multivariate analysis (MVA) (Table 3). Except for gender, they were all independent predictors of better survival. In the group of 59 patients irradiated with cRT ≥ 30 Gy patients irradiated with 45 Gy had better mOS compared to patients irradiated with doses 30–36 Gy, 17.2 months vs. 10.3 months, p = 0.03. (Figure 3) Patients with higher dose of consolida- tion RT had significantly longer 1-year OS (68%) than those with lower dose (30%), p = 0.01, but non- significantly longer 2-year OS (18% vs. 5%, p = 0.11). In the group of patients with cRT, we made an- other analysis. We included gender, age catego- ries, PS before RT, RT dose, T and N stage, meta- static locations, number of ChT cycles, number of metastatic lesions, PCI and timing of RT in UVA. Statistically significant predictors of longer mOS were PCI irradiation and higher RT dose. Both were analyzed in MVA (Table 4) and remained in- dependent predictors of improved survival. (PCI HR = 0.51, 95% CI 0.27–0.96; higher RT dose HR = 0.47, 95% CI 0.25–0.87). Discussion Thoracic irradiation has never been considered such an important part of ED-SCLC treatment as chemotherapy. Since the pivotal study of Jeremic et al. two decades ago, who were the first to show importance of RT in ED SCLC, only lately intro- duction of modern RT techniques with less toxicity rose interest again for the use of RT.18 Survival of patients with chemotherapy only and those who also had consolidation radiotherapy Our analysis showed that cRT significantly im- proved mOS compared to patients who had ChT only, 11.1 months vs. 7.6 months. Those patients also had significantly longer 1-year OS (44% vs. 23%) and non-significantly longer 2-year OS (10% vs. 5%). Apart from cRT, independent predictors of survival were also PCI and higher number of ChT cycles delivered. Unfortunately, the response to ChT could not be included to our analysis, as due to retrospective nature of this study the response to ChT was not uniformly evaluated. How results of our study compares to others is presented in Table 5. In a retrospective study of 119 Radiol Oncol 2020; 54(3): 353-363. Stanic K et al. / Consolidation radiotherapy in extended disease small cell lung cancer358 Gy.10 Study by Yee et al. included only 33 patients, all with PCI and cRT (40 Gy), but their reported mOS of 8.3 months is lower than ours.11 Another small retrospective study of 19 patients with cRT 40 Gy in 15 fraction reported mOS 14 months with 1-year and 2-year OS 58% and 14%.12 Difference in the results of these studies show that survival benefit could not be attributed to RT only, but also to the increased chances of those patients who re- mained in a better shape and fitter at the time of disease progression to receive subsequent lines of chemotherapy. Data from SEER analysis on al- most 7000 patients also provide evidence that ra- diotherapy for thoracic lesion and any metastatic sites could significantly improve the OS, except for brain metastasis.13 Three prospective randomized trials researched impact of RT on survival in ED SCLC.8,9,18 Trial by Jeremic et al. differs in many ways from more recently reported studies. They used accelerated hyperfractionation (54 Gy in 36 fractions) with concomitant ChT after 3 cycles of induction ChT and additional 2 cycles after RT in one group or after 5 cycles of ChT in another, both groups also eligible for PCI. They studied combined modal- ity treatment rather than cRT. The reported mOS was excellent for those who received RT early (17 months) as compared to those who received late RT (6–8 months).18 Another concern regarding hy- perfractionated RT is that is delivered twice daily (BID) and is technically challenging for patients with bilateral mediastinal lesions, which repre- sented the majority in our population. Further, patients selected for combined modality treatment, which incorporates BID RT must have excellent performance status and baseline pulmonary func- tion. In our study more than 10% of patients had PS 2-3 before cRT and unfortunately in more than half of patients PS could not be reliably retrieved from medical records. Phase III EORTC study (CREST) included pat- ents with PS 0–2 without brain and pleural metas- tases. Responders after 4–6 cycles of ChT and re- sidual disease in the thorax were treated with irra- diation of 30 Gy in 10 fractions.8 Contrary to our re- sults, no benefit was shown for added RT after ChT regarding mOS, which reported to be 8 months in both groups and for 1-year OS (33% for ChT with cRT vs. 28% for ChT group only). However, they reported significant difference in 2-year OS 13% vs. 3% (p = 0.004). It should, however, be noted that mOS was calculated from the randomization while mOS from diagnosis (as calculated in our analysis) was 12 months. TABLE 3. Univariate and multivariate analysis of overall survival for patients with cRT vs no cRT (n = 187) p Univariate analysis p Multivariate analysis HR (95% CI) HR (95% CI) cRT < 0.001 1.73 (1.27–2.34) 0.01 1.52 (1.10–2.09) no yes Gender 0.042 1.17 (1.00–1.37) 0.68 1.03 (0.87–1.21) Male Female Age 0.25 1.19 (0.88–1.62) > 65 < 65 Number of cycles received < 0.001 3.23 (2.33–4.47) < 0.001 3.11 (2.22–4.35) < 4 > 4 T stage 0.98 1.00 (0.67–1.50) T1, 2 T3, 4 N stage 0.16 1.08 (0.96–1.22) N0-2 N3 Metastases location Brain no/yes 0.61 0.91 (0.64–1.29) Liver no/yes 0.40 1.13 (0.84–1.52) Bone no/yes 0.75 0.94 (0.67-1.33) Adrenal gland no/yes 0.62 1.09 (0.76–1.57) Other no/yes 0.18 1.21 (0.90–1.63) Number of metastatic locations 0.68 1.06 (0.79–1.42) 1 > 2 PCI < 0.001 0.49 (CI 0.32–0.76) 0.015 1.59 (1.09–2.32) No Yes cRT = consolidation radiotherapy; N = lymph nodes; PCI = prophylactic cranial irradiation; T = tumour Radiol Oncol 2020; 54(3): 353-363. Stanic K et al. / Consolidation radiotherapy in extended disease small cell lung cancer 359 More aggressive thoracic irradiation was given in RTOG 0937 trial with 45 Gy in 15 fractions.9 Reported median OS (15.8 months) was better than anticipated and much better than in CREST and our study. Unlike all other studies, they reported better mOS for ChT only group (15.8 months) than for ChT plus RT group (13.8 months), though the difference was not statistically significant. 1-year OS was similar, surprisingly higher for ChT only than for ChT plus cRT group (60.1% vs. 50.8%). Two meta-analyses were published. The first, published by Palma et al. in 2015 included 2 stud- ies with 604 patients, while the second published in 2019 by Rathod et al. added also 86 patients from prematurely closed RTOG 0937 data.19,20 First me- ta-analysis found increased OS (p = 0.01), while the second failed to show improvement in overall sur- vival by adding cRT to ChT, (p = 0.36). Effect of consolidation radiotherapy dose on survival We found that patients who had been irradiated with higher dose (45 Gy in 18 fractions) had bet- ter mOS compared to those who received lower doses 30–36 Gy (in 10–12 fractions), 17.2 months vs. 10.3 months. Patients with higher dose of cRT had better 1-year OS (68%) than those with lower dose (30%) and also better 2-year OS (18% vs. 5%). Not many studies looked into dose difference for cRT. In retrospective study including 306 pa- tients of whom 170 received cRT, those with higher RT dose (BED > 50 Gy) had longer 2y-OS, 32.3% vs. 17% (p < 0.001), respectively.21 In recently pub- lished retrospective analysis of National Cancer Database that included 3280 patients they also re- ported that patients treated with the dose at least 45 Gy had better survival; 1-year OS was 58.1% and 2-year OS was 25.2% compared to 43.8% and 15.1% for lower dose.22 Our results for 1-year OS compare favorable, but 2-year OS data are lower, suggesting our subsequent treatments were not as effective. In CREST study, cRT dose used was 30 Gy in 10 fractions. The relative high intrathoracic failure rate of 42% indicated that this dose might be insuf- ficient to eliminate all the residual disease. In addi- tional analysis from CREST study, for patients with complete intrathoracic response no benefit of TRT was observed. They concluded that TRT should be offered to patients with a good or partial response after chemotherapy, but not to those without resid- ual disease in the thorax. It appears that the greater the volume of the residual disease in the thorax is, the higher dose is needed to eliminate the tumor. TABLE 4. Univariate and multivariate analysis of overall survival for higher vs. lower dose of consolidation radiotherapy p Univariate analysis p Multivariate analysis HR (95% CI) HR (95% CI) Dose 0.023 0.49 (0.27–0.90) 0.018 0.47 (0.25–0.87) 45 Gy 30-36 Gy Gender 0.17 1.4 (0.86–2.27) Male Female Age 0.38 1.25 (0.75–2.09) > 65 < 65 PS before RT 0.089 1.94 (0.90–4.18) 2–3 0–1 Number of ChT cycles 0.065 1.78 (0.96–3.31) < 4 > 4 T stage 0.34 0.72 (0.37–1.40) T1–2 T3–4 N stage 0.28 1.32 (0.79–2.20) N0–2 N3 Metastases location Brain da/ne 0.52 1.2 (0.68–2.11) Liver da/ne 0.39 1.22 (0.76–1.92) Bone da/ne 0.46 1.24 (0.70–2.21) Adrenal gland da/ne 0.98 0.99 (0.59–1.67) Other 0.84 0.95 (0.58–1.56) Number of metastatic locations 0.43 0.82 (0.51–1.33) 1 > 2 Timing of RT 0.71 1.13 (0.59–2.16) < 4 weeks after ChT > 4 weeks after ChT PCI 0.04 0.56 (CI 0.32–0.97) 0.037 0.51 (0.27–0.95) Yes No ChT = chemotherapy; cRT = consolidation radiotherapy; N = lymph nodes; PS = performance status; RT = radiatiotherapy; T = tumour Radiol Oncol 2020; 54(3): 353-363. Stanic K et al. / Consolidation radiotherapy in extended disease small cell lung cancer360 However, dose restrictions to the organs at risk and consequent toxicity limit the actual received dose. Number of metastases was not predictive fac- tor for survival in our analysis. Contrary to that, in recent retrospective publications it was shown that tumor burden of metastatic disease should be taken into account when treating ED SCLC patients, since those with ≥2 metastases had significantly worse outcome than those with only one metastasis.23,24 No difference of timing was found in our sur- vival analysis if RT started before or after 4 weeks after ChT completion. In RTOG 0937 trial and one retrospective Chinese study also no difference was found in survival for patients who received RT ear- ly or late.9,25 On the contrary, meta-analysis for lim- ited SCLC, showed that earlier or shorter RT brings 7.7% advantage in 5-year survival.26 In our study PCI was independent predictor of better survival, although only 21.9% of patients received one. Our previous publication, focused on impact of PCI on survival in patients with LD- SCLC, also showed that only low number of pa- tients (6%) actually received PCI in routine clinical setting, nevertheless OS was improved with PCI.27 As our analysis is retrospective, this reflects real clinical situation. However, the reason why such a low number of patients actually received PCI is unclear. PCI as independent predictor of survival was reported also in retrospective study by Xu et al.21 PCI in ED-SCLC was studied in EORTC con- ducted prospective study that showed reduced incidence of symptomatic brain metastases and improved 1-year OS (27% vs. 13.3%, HR 0.68, p = 0.003). That study, however, was highly criticized due to the insufficient imaging prior to PCI.9 Japanese prospective study evaluated 224 patients with ED-SCLC who performed MRI prior to ran- domization to PCI or observation with MRI.28 The study was terminated prematurely due to lower rate of brain metastases in PCI arm (40%) vs. MRI observation only (64%), but they found no signifi- cant difference in 1-year OS. None of our patients had MRI prior to PCI and only one third had CT evaluation, indicating that imaging in routine TABLE 5. Trials of consolidation radiotherapy (cRT) in extended disease small cell lung cancer (ED-SCLC) Author/Trial, reference Publication year Type of study Patients -years enrolled Number of patients Patient selection Thoracic irradiation dose scheme mOS 1-year OS 2-year OS Jeremic18 1999 P 1988–1993 109 ED-SCLC with CR at metastatic sites and at least PR in thorax 54 Gy in 36 fractions, BID 17 m vs. 11 m* P = 0.041 65% vs. 46% P ≤ 0.05 38% vs. 28% P ≤ 0.05 Slotman (CREST)8 2015 P 2009–2012 495 ED-SCLC with any response to ChT 30 Gy in 10 fractions 8 m vs. 8 m 33% vs. 28% P = 0.066 13% vs. 3% P = 0.004 Gore (RTOG 0937)9 2017 P 2010–2016 97 ED-SCLC (1-4 extracranial m., any response to ChT 40 Gy in 15 fractions 15.8 m vs. 13.8 m P = 0.21 50.8% vs. 60.1% P = 0.21 NR Zhu10 2011 R 2003–2006 119 ED-SCLC 40–60 Gy 17 m vs. 9.3 mP = 0.014 NR 35% vs. 17% Giuliani12 2011 R 2005–2009 19 ED-SCLC with minimal metastatic disease 36–45 Gy 14 m 58% 14% Yee11 2012 R 2008–2009 32 ED-SCLC 40 Gy in 15 fractions 8.3 m NR NR Zhan13 (SEER database) 2018 R 2010–2012 6812 ED-SCLC from SEER database Different, not reported 9 m vs. 7 m; P < 0.001 8 m vs. 6 m for polymetastases P < 0.05 NR NR Stanic 2020 R 2010–2014 187 ED-SCLC 30–45 Gy 11.1 m vs. 7.6 m P < 0.001 44% vs. 23% P = 0.0025 10% vs. 5% P = 0.19 * group 1 CR/PR and RT vs. group 2 CR/PR, no RT; BID = twice daily; ChT = chemotherapy; CR = complete response; ED-SCLC = extended disease small cell lung cancer; m = months; mOS = median overall survival; NR-not reported; OS = overall survival; P = prospective; PR = partial response; R = retrospective Radiol Oncol 2020; 54(3): 353-363. Stanic K et al. / Consolidation radiotherapy in extended disease small cell lung cancer 361 clinical practice should improve. In CREST study PCI dose was not uniform (20–30 Gy in 5–15 frac- tions) with unusual hypofractionated dose (20 Gy in 5 fraction) used in majority of patients (62%).8 It was delivered concurrently with thoracic irradia- tion in 88% of patients, while other studies used sequential approach and uniform dose of 25 Gy in 10 fractions.9,18 Difference in pre-PCI imaging and dose delivered as well as timing of PCI show diversified approach on this not fully researched area.29 Consolidation radiotherapy and immunotherapy Immunotherapy (IT) has been successfully incor- porated into the treatment of metastatic non-small cell lung cancer (NSCLC) either as combination of ChT and IT or as mono-IT and lately also in stage III as consolidation treatment after concomitant chemoradiotherapy.30-39 Recently, two randomized studies confirmed efficacy of IT also for the treatment in ED-SCLC. IMpower 133 study was the first to show improved OS in patients treated with atezolizumab combined with ChT (12.3 months) as compared to ChT plus placebo (10.3 months). 1-year OS rate was 51.7% in the atezolizumab group and 38.2% in the pla- cebo group.16 Consolidation RT was not permitted, while patients could have PCI. The same criteria about cRT and PCI were also applied in CASPIAN study with durvalumab.17 Again, IT combination showed increased results, mOS in ChT-IT arm was 13 months and 10.3 months in ChT only arm and 1-year OS was 54% vs. 40%, respectively. Though PCI was allowed in the non IT group, only 8% of patients received it. If the inclusion of immuno- therapy would prove to reduce the incidence of brain metastases in ES-SCLC considerably in fu- ture trials as suggested from present studies, then PCI and consequently neurotoxic sequels could be omitted in the future. The decision about skipping cRT might be more challenging. Survival data from current studies has not shown superior survival in first line treatment with ChT-IT in ED-SCLC com- pared to studies with ChT and cRT. Could cRT be combined with IT during the consolidation phase? First reported data indicate that the combination is tolerable, however trials are still ongoing and safety as well as survival results are expected in the future.40 As previously reported, the use of thoracic RT may enhance the effect of IT by influencing the immune system and its interactions with cancer cells and tumors, recruiting anti-tumor immune cells, increasing the exposure of tumor antigens, and improving cross-presentation of these anti- gens to the adaptive immune system.41-43 Beside retrospective nature of our analysis we should acknowledge several other limitations of our research. The irradiation dose was not speci- fied by the protocol or any other department regu- lation and the decision was under the discretion of treating physician. Larger tumors (T3-4, N3) were more frequently irradiated with lower dose, but this does not necessarily mean that larger tumors would not be feasible to the treatment with larger doses. Unfortunately, we were not able to retrieve reliable information about PS before RT in half of patients, reflecting real clinical practice. This would be valuable information as treatment decision in clinical practice is greatly influenced by PS and consequently might influence survival data. Due to the fact that not all patients were treated with ChT in our institution, PS before ChT could not be included in UVA and MVA. Also, the response to initial Cht as one of the main prognostic factors of cRT efficacy according to the published data, is missing, since not all the patients were treated at our institution. However, all the patients were dis- cussed at the MTB before the treatment which at least partially reduces this shortcoming. Conclusions Our analysis has shown that cRT improved mOS as compared to ChT alone of the ED-SCLC patients treated at our institution. Consolidation RT, higher number of ChT cycles and profilactic cranial irra- diation (PCI) were independent prognostic factors for better survival. For patients who received cRT, only higher doses and PCI had impact on surviv- al regardless of number of ChT cycles received. Whether cRT and PCI will still be players in the era of immunotherapy is unknown and will be shown in further trials. References 1. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011; 378: 1741-55. doi: 10.1016/S0140-6736(11)60165-7 2. Cancer in Slovenia 2014. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2017. 3. Mitchell MD, Aggarwal C, Tsou AY, Torigian DA, Treadwell JR. Imaging for the pretreatment staging of small cell lung cancer: a systematic review. Acad Radiol 2016; 23: 1047-56. doi: 10.1016/j.acra.2016.03.017 Radiol Oncol 2020; 54(3): 353-363. Stanic K et al. / Consolidation radiotherapy in extended disease small cell lung cancer362 4. Niho S, Fujii H, Murakami K, Nagase S, Yoh K, Goto K, et al. Detection of un- suspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer. Lung Cancer 2007; 57: 328-33. doi.org/10.1016/j.lungcan.2007.04.001 5. Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, on behalf of the ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi99-105. doi: 10.1093/annonc/mdt178 6. National Comprehensive Cancer Network. NCCN guidelines version 2.2020. Small cell lung cancer Nov 15 2019. [Cited 2020 Feb 15]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf 7. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357: 664-72. doi: 10.1056/NEJMoa071780 8. Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY5 Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015; 385: 36-42. doi: 10.1016/S0140-6736(14)61085-0 9. Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, et al. Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol 2017; 12: 1561-70. doi: 10.1016/j.jtho.2017.06.015 10. Zhu H, Zhou Z, Wang Y, Bi N, Feng Q, Li J, et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis. Cancer 2011; 117: 5423-31. doi: 10.1002/ cncr.26206 11. Yee D, Butts C, Reiman A, Joy A, Smylie M, Fenton D, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer. Radiother Oncol 2012; 102: 234-8. doi: 10.1016/j. radonc.2011.08.042 12. Giuliani ME, Atallah S, Sun A, et al. Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radio- therapy. Clin Lung Cancer 2011; 12: 375-9. doi: 10.1016/j.cllc.2011.03.028 13. Zhang R, Li P, Li Q, Qiao Y, Xu T, Ruan P, et al. Radiotherapy improves the sur- vival of patients with extensive-disease small-cell lung cancer: a propensity score matched analysis of surveillance, epidemiology, and end results data- base. Cancer Manag Res 2018; 10: 6525-35. doi: 10.2147/CMAR.S174801 14. Jeremic B, Gomez-Caamano A, Dubinsky P, Cihoric N, Casas F, Filipovic N. Radiation therapy in extensive stage small cell lung cancer. Front Oncol 2017; 7: 169. doi: 10.3389/fonc.2017.00169 15. Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res 2016; 5: 26-38. doi: 10.3978/j.issn.2218-6751.2016.01.13. 16. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018; 379: 2220-9. doi: 10.1056/NEJMoa1809064 17. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum-etoposide in first- line treatment of extensive-stage small-cell lung cancer (CASPIAN): a ran- domised, controlled, open-label, phase 3 trial. Lancet 2019; 394: 1929-39. doi: 10.1016/S0140-6736(19)32222-6 18. Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, et al. Role of radiation therapy in the combined modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999; 17: 2092-9. doi: 10.1200/JCO.1999.17.7.2092 19. Palma DA, Warner A, Louie AV, Senan S, Slotman B, Rodrigues GB. Thoracic radiotherapy for extensive stage small-cell lung cancer: a meta-analysis. Clin Lung Cancer 2016; 17: 239-44. doi: 10.1016/j.cllc.2015.09.00 20. Rathod S, Jeremic B, Dubey A, Giuliani M, Bashir B, Chowdhury A, et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Eur J Cancer 2019; 110: 110-9. doi: 10.1016/j.ejca.2019.01.003 21. Xu LM, Zhao LJ, Charles B , Simone CB 2nd, Cheng C, Kang M, et al. Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer. Radiother Oncol 2017; 125: 331-7. doi: 10.1016/j.radonc.2017.10.005 22. Hasan S, Renz P, Turrisi A, Colonias A, Finley G, Wegner RE. Dose escalation and associated predictors of survival with consolidative thoracic radio- therapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysis. Lung Cancer 2018; 124: 283-90. doi: 10.1016/j.lungcan.2018.08.016 23. Xu LM, Cheng C, Kang M, Luo J, Gong LL, Pang QS, et al. Thoracic radio- therapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer. Sci Rep 2017; 7: 9255. doi: 10.1038/s41598-017- 09775-0 24. Fukui T, Itabashi M, Ishihara M, Hiyoshi Y, Kasajima M, Igawa S, et al. Prognostic factors affecting the risk of thoracic progression in extensive- stage small cell lung cancer. BMC Cancer 2016; 16: 197. doi:10.1186/ s12885-016-2222-4 25. Luo J, Xu L, Zhao L, Cao Y, Pang Q, Wang J, et al. Timing of thoracic radiother- apy in the treatment of extensive-stage small-cell lung cancer: important or not? Radiat Oncol 2017; 12: 42. doi: 10.1186/s13014-017-0779-y 26. De Ruysscher D, Lueza B, Le Péchoux C, Johnson DH, O’Brien M, Murray N, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol 2016; 27: 1818-28. doi: 10.1093/annonc/mdw263 27. Stanic K, Kovac V. Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana. Radiol Oncol 2010; 44: 180-6. doi: 10.2478/v10019-010-0038-4 28. Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open- label, phase 3 trial. Lancet Oncol 2017; 18: 663-71. doi: 10.1016/S1470- 2045(17)30230-9 29. Rusthoven CG, Kavanagh BD. Prophylactic cranial irradiation (PCI) versus active MRI surveillance for small cell lung cancer: the case for equipoise. J Thorac Oncol 2017; 12: 1746-54. doi: 10.1016/j.jtho.2017.08.016 30. Hui R, Gandhi L, Costa EC, Felip E, Ahn MJ, Eder JP, et al. Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pem- brolizumab (pembro). J Clin Oncol 2016; 34: Abstr nr 9026. 31. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-28. doi: 10.1056/NEJMoa1501824 32. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, ad- vanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-50. doi: 10.1016/S0140-6736(15)01281-7 33. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-33. doi: 10.1056/NEJMoa1606774 34. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizum- ab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016; 17: 1497-508. doi: 10.1016/S1470-2045(16)30498-3 35. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35. doi: 10.1056/NEJMoa1504627 36. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39. doi: 10.1056/NEJMoa1507643 37. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previ- ously treated non-small-cell lung cancer (POPLAR): a multicentre, open- label, phase 2 randomised controlled trial. Lancet 2016; 387: 1837-46. doi: 10.1016/S0140-6736(16)00587-0 38. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342-50. doi: 10.1056/NEJMoa1809697 39. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung can- cer. N Engl J Med 2017; 377: 1919-29. doi: 10.1056/NEJMoa1709937 Radiol Oncol 2020; 54(3): 353-363. Stanic K et al. / Consolidation radiotherapy in extended disease small cell lung cancer 363 40. Verma V, Cushman TR, Selek U, Tang C, Welsh JW. Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single- Institutional Phase I/II Trials. Int J Radiat Oncol Biol Phys 2018; 101: 1141-8. doi: 10.1016/j.ijrobp.2018.04.054 41. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 2015; 1: 1325-32. doi: 10.1001/jamaoncol. 2015.2756 42. Vrankar M, Stanic K. Long-term survival of locally advanced stage III non- small cell lung cancer patients treated with chemoradiotherapy and per- spectives for the treatment with immunotherapy. Radiol Oncol 2018; 52: 281-8. doi: 10.2478/raon-2018-0009 43. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint block- ade immunotherapy: radiosensitisation and potential mechanisms of syner- gy. Lancet Oncol 2015; 16: e498-509. doi: 10.1016/S1470-2045(15)00007-8